{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:19:14Z","timestamp":1791901154185,"version":"4.3.4"},"reference-count":38,"publisher":"Pharmaceutical Society of Japan","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2024,1,1]]},"DOI":"10.1248\/bpb.b23-00672","type":"journal-article","created":{"date-parts":[[2023,12,31]],"date-time":"2023-12-31T17:14:13Z","timestamp":1704042853000},"page":"159-165","source":"Crossref","is-referenced-by-count":10,"title":["Regulation of Chloride Channels by Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced \u03b1-Defensin 5"],"prefix":"10.1248","volume":"47","author":[{"given":"Ippei","family":"Uemura","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Hokkaido University of Science"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuko","family":"Takahashi-Suzuki","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University of Science"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiya","family":"Kita","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University of Science"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmaceutics & Therapeutics, Faculty of Pharmaceutical Sciences, Hokkaido University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University of Science"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Iseki","sequence":"additional","affiliation":[{"name":"Education Research Center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Hokkaido University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Satoh","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University of Science"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Le T, Gerber DE. Newer-generation EGFR inhibitors in lung cancer: how are they best used? Cancers <\/i>(Basel), 11<\/b>, 366 (2019).","DOI":"10.3390\/cancers11030366"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Miller VA, Hirsh V, Cadranel J, Chen Y, Park K, Kim S, Zhou C, Su W, Wang M, Sun Y, Heo DS, Crino L, Tan E, Chao T, Shahidi M, Cong XJ, Lorence RM, Yang JC. Afatinib versus<\/i> placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b\/3 randomised trial. Lancet Oncol.<\/i>, 13<\/b>, 528\u2013538 (2012).","DOI":"10.1016\/S1470-2045(12)70087-6"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Wang Z. ErbB receptors and cancer. Methods Mol. Biol.<\/i>, 1652<\/b>, 3\u201335 (2017).","DOI":"10.1007\/978-1-4939-7219-7_1"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Schaefer G, Shao L, Totpal K, Akita RW. Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression. Cancer Res.<\/i>, 67<\/b>, 1228\u20131238 (2007).","DOI":"10.1158\/0008-5472.CAN-06-3493"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol.<\/i>, 19<\/b>, 183\u2013232 (1995).","DOI":"10.1016\/1040-8428(94)00144-I"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) De S, Dermawan JK, Stark GR. EGF receptor uses SOS1 to drive constitutive activation of NF\u03baB in cancer cells. Proc. Natl. Acad. Sci. U.S.A.<\/i>, 111<\/b>, 11721\u201311726 (2014).","DOI":"10.1073\/pnas.1412390111"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Yamada S, Go M, Nishimura M, Usami E, Kimura M, Iwasaki F, Yoshimura T. Evaluation of the utility of the original nutrition table for the patients undergoing monotherapy with oral anticancer agents. Iryou Yakugaku (Jpn. J. Pharm. Heal. Care Sci.)<\/i>, 47<\/b>, 163\u2013170 (2021).","DOI":"10.5649\/jjphcs.47.163"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) P\u00e9rez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabarbara P, Bonomi P. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J. Clin. Oncol.<\/i>, 22<\/b>, 3238\u20133247 (2004).","DOI":"10.1200\/JCO.2004.11.057"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Sequist LV, Yang JC, Yamamoto N, O\u2019Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol.<\/i>, 31<\/b>, 3327\u20133334 (2013).","DOI":"10.1200\/JCO.2012.44.2806"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Goto K, Nishio M, Yamamoto N, Chikamori K, Hida T, Maemondo M, Katakami N, Kozuki T, Yoshioka H, Seto T, Fukuyama T, Tamura T. A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC). Lung Cancer<\/i>, 82<\/b>, 109\u2013114 (2013).","DOI":"10.1016\/j.lungcan.2013.07.003"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Maemondo M, Inoue A, Kobayashi K, et al.<\/i> Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med.<\/i>, 362<\/b>, 2380\u20132388 (2010).","DOI":"10.1056\/NEJMoa0909530"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Harada Y, Sekine H, Kubota K, Sadatomi D, Iizuka S, Fujitsuka N. Calcium-activated chloride channel is involved in the onset of diarrhea triggered by EGFR tyrosine kinase inhibitor treatment in rats. Biomed. Pharmacother.<\/i>, 141<\/b>, 111860 (2021).","DOI":"10.1016\/j.biopha.2021.111860"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Van Sebille YZ, Gibson RJ, Wardill HR, Bowen JM. ErbB small molecule tyrosine kinase inhibitor (TKI) induced diarrhoea: chloride secretion as a mechanistic hypothesis. Cancer Treat. Rev.<\/i>, 41<\/b>, 646\u2013652 (2015).","DOI":"10.1016\/j.ctrv.2015.05.011"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Kunzelmann K, Centeio R, Wanitchakool P, Cabrita I, Benedetto R, Saha T, Hoque KM, Schreiber R. Control of ion transport by Tmem16a expressed in murine intestine. Front. Physiol.<\/i>, 10<\/b>, 1262 (2019).","DOI":"10.3389\/fphys.2019.01262"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Duan T, Cil O, Thiagarajah JR, Verkman AS. Intestinal epithelial potassium channels and CFTR chloride channels activated in ErbB tyrosine kinase inhibitor diarrhea. JCI Insight.<\/i>, 4<\/b>, e126444 (2019).","DOI":"10.1172\/jci.insight.126444"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Ouellette AJ. Paneth cell \u03b1-defensins in enteric innate immunity. Cell. Mol. Life Sci.<\/i>, 68<\/b>, 2215\u20132229 (2011).","DOI":"10.1007\/s00018-011-0714-6"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Froy O. Regulation of mammalian defensin expression by toll-like receptor-dependent and independent signalling pathways. Cell. Microbiol.<\/i>, 7<\/b>, 1387\u20131397 (2005).","DOI":"10.1111\/j.1462-5822.2005.00590.x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Menendez A, Willing BP, Montero M, Wlodarska M, So CC, Bhinder G, Vallance BA, Finlay BB. Bacterial stimulation of the TLR-MyD88 pathway modulates the homeostatic expression of ileal paneth cell \u03b1-defensins. J. Innate Immun.<\/i>, 5<\/b>, 39\u201349 (2013).","DOI":"10.1159\/000341630"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) De S, Zhou H, DeSantis D, Croniger CM, Li X, Stark GR. Erlotinib protects against LPS-induced endotoxicity because TLR4 needs EGFR to signal. Proc. Natl. Acad. Sci. U.S.A.<\/i>, 112<\/b>, 9680\u20139685 (2015).","DOI":"10.1073\/pnas.1511794112"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Kelly P, Bajaj-Elliott M, Katubulushi M, Zulu I, Poulsom R, Feldman RA, Bevins CL, Dhaliwal W. Reduced gene expression of intestinal \u03b1-defensins predicts diarrhea in a cohort of African adults. J. Infect. Dis.<\/i>, 193<\/b>, 1464\u20131470 (2006).","DOI":"10.1086\/503747"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Ericksen B, Wu Z, Lu W, Lehrer RI. Antibacterial activity and specificity of the six human alpha-defensins. Antimicrob. Agents Chemother.<\/i>, 49<\/b>, 269\u2013275 (2005).","DOI":"10.1128\/AAC.49.1.269-275.2005"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Salzman NH, Chou MM, de Jong H, Liu L, Porter EM, Paterson Y. Enteric salmonella infection inhibits Paneth cell antimicrobial peptide expression. Infect. Immun.<\/i>, 71<\/b>, 1109\u20131115 (2003).","DOI":"10.1128\/IAI.71.3.1109-1115.2003"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C, Kraemer O, Himmelsbach F, Haaksma E, Adolf GR. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J. Pharmacol. Exp. Ther.<\/i>, 343<\/b>, 342\u2013350 (2012).","DOI":"10.1124\/jpet.112.197756"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Karlsson M, Zhang C, M\u00e9ar L, et al.<\/i> A single-cell type transcriptomics map of human tissues. Sci. Adv.<\/i>, 7<\/b>, eabh2169 (2021).","DOI":"10.1126\/sciadv.abh2169"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Yasuda G, Kobayashi M, Kubota A, Narumi K, Furugen A, Saito Y, Satoh T, Suzuki N, Iseki K. Analysis of \u03b1-defensin 5 secretion in differentiated Caco-2 cells: comparison of cell bank origin. Biol. Pharm. Bull.<\/i>, 44<\/b>, 275\u2013278 (2021).","DOI":"10.1248\/bpb.b20-00644"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Cadwell K, Liu JY, Brown SL, Miyoshi H, Loh J, Lennerz JK, Kishi C, Kc W, Carrero JA, Hunt S, Stone CD, Brunt EM, Xavier RJ, Sleckman BP, Li E, Mizushima N, Stappenbeck TS, Virgin HW 4th. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature<\/i>, 456<\/b>, 259\u2013263 (2008).","DOI":"10.1038\/nature07416"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Adolph TE, Tomczak MF, Niederreiter L, et al.<\/i> Paneth cells as a site of origin for intestinal inflammation. Nature<\/i>, 503<\/b>, 272\u2013276 (2013).","DOI":"10.1038\/nature12599"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Negoro S, Shimohata T, Hatayama S, Sato Y, Matsumoto M, Iba H, Aihara M, Uebanso T, Hamada Y, Nishikawa Y, Yamasaki S, Mawatari K, Takahashi A. Campylobacter jejuni<\/i> infection suppressed Cl\u2212<\/sup> secretion induced by CFTR activation in T-84 cells. J. Infect. Chemother.<\/i>, 20<\/b>, 682\u2013688 (2014).","DOI":"10.1016\/j.jiac.2014.07.007"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Reynolds A, Anderson EM, Vermeulen A, Fedorov Y, Robinson K, Leake D, Karpilow J, Marshall WS, Khvorova A. Induction of the interferon response by siRNA is cell type- and duplex length-dependent. RNA<\/i>, 12<\/b>, 988\u2013993 (2006).","DOI":"10.1261\/rna.2340906"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Kulka M, Dery R, Nahirney D, Duszyk M, Befus AD. Differential regulation of cystic fibrosis transmembrane conductance regulator by interferon gamma in mast cells and epithelial cells. J. Pharmacol. Exp. Ther.<\/i>, 315<\/b>, 563\u2013570 (2005).","DOI":"10.1124\/jpet.105.087528"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Matsumoto S, Miyagishi M, Akashi H, Nagai R, Taira K. Analysis of double-stranded RNA-induced apoptosis pathways using interferon-response noninducible small interfering RNA expression vector library. J. Biol. Chem.<\/i>, 280<\/b>, 25687\u201325696 (2005).","DOI":"10.1074\/jbc.M412784200"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Benedetto R, Cabrita I, Schreiber R, Kunzelmann K. TMEM16A is indispensable for basal mucus secretion in airways and intestine. FASEB J.<\/i>, 33<\/b>, 4502\u20134512 (2019).","DOI":"10.1096\/fj.201801333RRR"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Bowen JM, Mayo BJ, Plews E, Bateman E, Wignall A, Stringer AM, Boyle FM, Keefe DM. Determining the mechanisms of lapatinib-induced diarrhoea using a rat model. Cancer Chemother. Pharmacol.<\/i>, 74<\/b>, 617\u2013627 (2014).","DOI":"10.1007\/s00280-014-2519-4"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Takakuwa A, Nakamura K, Kikuchi M, Sugimoto R, Ohira S, Yokoi Y, Ayabe T. Butyric acid and leucine induce \u03b1-defensin secretion from small intestinal Paneth cells. Nutrients<\/i>, 11<\/b>, 2817 (2019).","DOI":"10.3390\/nu11112817"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Takahashi N, Kobayashi M, Ogura J, Yamaguchi H, Satoh T, Watanabe K, Iseki K. Immunoprotective effect of epigallocatechin-3-gallate on oral anticancer drug-induced \u03b1-defensin reduction in Caco-2 cells. Biol. Pharm. Bull.<\/i>, 37<\/b>, 490\u2013492 (2014).","DOI":"10.1248\/bpb.b13-00700"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Kubota A, Kobayashi M, Sarashina S, Takeno R, Yasuda G, Narumi K, Furugen A, Takahashi-Suzuki N, Iseki K. Gamma-aminobutyric acid (GABA) attenuates ischemia reperfusion-induced alterations in intestinal immunity. Biol. Pharm. Bull.<\/i>, 41<\/b>, 1874\u20131878 (2018).","DOI":"10.1248\/bpb.b18-00338"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Kubota A, Kobayashi M, Sarashina S, Takeno R, Okamoto K, Narumi K, Furugen A, Suzuki Y, Takahashi N, Iseki K. Reishi mushroom Ganoderma lucidum Modulates IgA production and alpha-defensin expression in the rat small intestine. J. Ethnopharmacol.<\/i>, 214<\/b>, 240\u2013243 (2018).","DOI":"10.1016\/j.jep.2017.12.010"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Al-Dasooqi N, Gibson R, Bowen J, Keefe D. HER2 targeted therapies for cancer and the gastrointestinal tract. Curr. Drug Targets<\/i>, 10<\/b>, 537\u2013542 (2009).","DOI":"10.2174\/138945009788488440"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/47\/1\/47_b23-00672\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T22:25:46Z","timestamp":1704493546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/47\/1\/47_b23-00672\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b23-00672","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,1]]},"article-number":"b23-00672"}}